Petredis Investment Advisors LLC purchased a new position in Johnson & Johnson (NYSE:JNJ – Get Rating) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 37,379 shares of the company’s stock, valued at approximately $6,603,000. Johnson & Johnson comprises about 1.2% of Petredis Investment Advisors LLC’s portfolio, making the stock its 22nd largest position.
Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. Nordwand Advisors LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter worth about $785,273,000. Edmp Inc. lifted its position in shares of Johnson & Johnson by 17,222.9% in the 4th quarter. Edmp Inc. now owns 3,223,265 shares of the company’s stock worth $18,247,000 after purchasing an additional 3,204,658 shares during the period. Vanguard Group Inc. lifted its position in shares of Johnson & Johnson by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after purchasing an additional 2,815,655 shares during the period. GQG Partners LLC lifted its position in shares of Johnson & Johnson by 64.4% in the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after purchasing an additional 2,547,378 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of Johnson & Johnson by 37.2% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock worth $1,179,219,000 after purchasing an additional 1,805,632 shares during the period. 67.94% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Stock Performance
Shares of JNJ stock opened at $165.03 on Wednesday. The company has a 50 day moving average price of $158.00 and a 200-day moving average price of $167.05. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $183.35. The firm has a market capitalization of $429.79 billion, a PE ratio of 34.53, a P/E/G ratio of 2.78 and a beta of 0.53. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35.
Johnson & Johnson Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be given a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 2.88%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Monday, May 22nd. Johnson & Johnson’s payout ratio is 94.56%.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on JNJ shares. UBS Group started coverage on shares of Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price target for the company. Guggenheim started coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target for the company. SVB Leerink lowered their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. StockNews.com started coverage on shares of Johnson & Johnson in a research report on Thursday, March 16th. They set a “strong-buy” rating for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $173.00.
Insider Activity at Johnson & Johnson
In related news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.20% of the stock is currently owned by company insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Do Bank Stocks Go Up When Interest Rates Rise?
- How to Invest in Vertical Farming Stocks
- Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
- Ecolab: Slow And Steady Wins The Race
- MGM’s Hot Hand Is All In For A Rally, After This Small Break
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
